Voices
Dickran Kazandjian: How Do New Data Reshape CAR T and Bispecific Use at Early Relapse?

Dickran Kazandjian: How Do New Data Reshape CAR T and Bispecific Use at Early Relapse?

Dickran Kazandjian, Professor of Medicine at Sylvester Comprehensive Cancer Center, shared on X:

“Multiple Myeloma EHA and ASCO® 2026 Highlights and Controversies: How Do MonumenTAL-3 and Other New Data Reshape CAR T and Bispecific Use at Early Relapse? 

A chat with C. Ola Landgren, Dr. Ken Shain and Ben Derman.

Watch the video.”

You can also read: Multiple Myeloma in 2026: Comprehensive Clinical Update

Dickran Kazandjian: How Do New Data Reshape CAR T and Bispecific Use at Early Relapse?

ASCO 2026 Ben Derman C. Ola Landgren cancer Dickran Kazandjian EHA Ken Shain MonumenTAL-3 multiple myeloma OncoDaily Oncology